| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000032370 |
| Receipt No. | R000036920 |
| Official scientific title of the study | The influence of paclitaxel in drug-drug interaction via hepatic organic anion transporter |
| Date of disclosure of the study information | 2018/04/24 |
| Last modified on | 2018/10/06 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | The influence of paclitaxel in drug-drug interaction via hepatic organic anion transporter | |
| Title of the study (Brief title) | The influence of paclitaxel to liver organic anion transporter | |
| Region |
|
|
| Condition | |||
| Condition | Non-small cell lung cancer | ||
| Classification by specialty |
|
||
| Classification by malignancy | Malignancy | ||
| Genomic information | YES | ||
| Objectives | |
| Narrative objectives1 | To assess the plasma concentrations of endogenous substrates for OATP before and after paclitaxel administration |
| Basic objectives2 | Pharmacokinetics |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Plasma concentrations of endogenous substrates for OATP before and after paclitaxel administration |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Paclitaxel | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Histologically or cytologically confirmed non-small cell lung cancer
2) Unresectable advanced or recurrent disease 3) Age is over 20 years. 4) Performance status (ECOG) is 0 to 1 5) Adequate organ function, evidenced by following laboratory results within 14 days prior to starting chemotherapy Absolute neutrophil count>1,500/mm3 Platelet count>150,000/mm3 Hemoglobin>9.0g/dL AST and ALT<2.5 times the upper limit of normal(ULN) Total bilirubin<1.5mg/dL 6) Signed, written informed concent is obtained |
|||
| Key exclusion criteria | 1) Severe complication (e.g., uncontrollable diabetis mellitus, liver disease)
2) Serological positive for HBs-antigen or HCV-antibody 3) Active synchronous cancer 4) Severe psychiatric disorder 5) Pregnant or lactating women, or men and women without wanting pregnancy 6) Severe hypersensitivity to medicine 7) Patients who were judged inappropriate for the study |
|||
| Target sample size | 10 | |||
| Research contact person | |
| Name of lead principal investigator | Hiroo Ishida |
| Organization | Showa University School of Medicine |
| Division name | Division of Medical Oncology, Department of Medicine |
| Address | 1-5-8 Hatanodai, Shinagawa-ku, Tokyo |
| TEL | 03-3784-8000 |
| hishida@med.showa-u.ac.jp | |
| Public contact | |
| Name of contact person | Hiroo Ishida |
| Organization | Showa University School of Medicine |
| Division name | Division of Medical Oncology, Department of Medicine |
| Address | 1-5-8 Hatanodai, Shinagawa-ku, Tokyo |
| TEL | 03-3784-8000 |
| Homepage URL | |
| hishida@med.showa-u.ac.jp | |
| Sponsor | |
| Institute | Showa University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Showa University |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036920 |